Could a weekly shot fix hormone chaos in teens with PCOS?

NCT ID NCT07169136

Recruiting now Disease control Sponsor: Nemours Children's Clinic Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether a weekly injection of semaglutide (a GLP-1 drug used for obesity) can improve the brain's reproductive hormone signals in obese adolescent girls with polycystic ovary syndrome (PCOS). Twenty girls aged 12–18 will receive the drug plus lifestyle advice for 16 weeks. Researchers will measure changes in overnight hormone pulses and body composition to see if the treatment helps restore normal reproductive function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide (a GLP-1 receptor agonist, given as a weekly injection)
What this could lead to: If it works, this could point toward a treatment that helps restore normal menstrual cycles and hormone balance in obese adolescents with PCOS.
What could go wrong: This is a very small, early-phase study with only 20 participants, so results may not apply widely. The drug may not improve hormone rhythms, and side effects like nausea or vomiting are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY (DISORDER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Menstruation Disturbances Obesity obesity disorder polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY (DISORDER) POLYCYSTIC OVARIAN SYNDROME IN ADOLESCENT FEMALES

Contacts and locations

Locations

Nemours Children's Clinic
RECRUITING

Jacksonville, Florida, 32207, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.